Evidence map›Paper›PMID 23227519›Full record

ArticleJournal of translational medicine2012

An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma.

Mariko Masuda, Yasuhiro Miki, Shuko Hata, Kiyoshi Takagi, Minako Sakurai, Katsuhiko Ono, Koyu Suzuki, Yang Yang, Eriko Abe, Hisashi Hirakawa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Metformin and long non-coding RNAs in breast cancer.Journal of translational medicine · 2023
    Review
  5. Molecular mechanism of theAnnals of translational medicine · 2023
    Article
  6. MiR-7 in Cancer Development.Biomedicines · 2021
    Review
  7. Article
  8. Deregulation of miRNA inJournal of clinical medicine · 2019
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Role of microRNA-7 in digestive system malignancy.World journal of gastrointestinal oncology · 2016
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Mariko MasudaDepartment of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yasuhiro Miki
Shuko Hata
Kiyoshi Takagi
Minako Sakurai
Katsuhiko Ono
Koyu Suzuki
Yang Yang
Eriko Abe
Hisashi Hirakawa
Takanori Ishida
Takashi Suzuki
Noriaki Ohuchi
Hironobu Sasano
Tohoku University · JPSt. Luke's International Hospital · JPKKR Tohoku Kosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEstrogen plays an important role in the development of estrogen-dependent breast carcinoma. Recently, several studies demonstrated a possible involvement of several micro RNAs (miRNAs) in the development of resistance to endocrine therapy in breast cancer patients, but the correlation between estrogen actions and miRNA expression in breast carcinoma still remains largely unknown. Therefore, in this study, we examined the in vitro effects of estrogen upon miRNA expression profiles in breast carcinoma.

methodsWe first screened the miRNA expression profiles induced by 17β-Estradiol (E2) using RT2 miRNA PCR Array in the ER-positive breast carcinoma cell line MCF-7. We identified miR-7 as the important miRNA associated with estrogen actions in these cells and further examined the changes of estrogen-dependent EGFR expression by miR-7 in ER-positive or -negative breast carcinoma cell lines including MCF-7. We also evaluated the correlation between miR-7 and EGFR expression in breast carcinoma cells derived from 21 patients using laser capture microdissection combined with quantitative reverse transcriptase-PCR.

resultsSeventeen miRNAs were significantly induced by E2 treatment in the MCF-7 cell line. Among 17 miRNAs induced by estradiol treatment, only miR-7 expression was significantly decreased by subsequent ICI treatment. The expression of miR-7 was up-regulated 2.94-fold by E2 treatment. miR-7 was reported to suppress epidermal growth factor receptor (EGFR) expression in several human malignancies. Transfection of miR-7 significantly suppressed EGFR mRNA levels in MCF-7 cells. Depletion of E2 from cell culture media also increased the expression level of EGFR mRNA in MCF-7 and T-47D cells but not in ER-negative, MDA-MB-231 and SK-BR-3 cells. We also evaluated the status of miR-7 in breast carcinoma tissues, but the correlation between the status of miR-7 and EGFR in carcinoma cells isolated by laser capture microscopy was not detected.

conclusionsThese results suggest that miR-7 may play a role in the development of resistance to endocrine therapy in breast cancer patients through regulating EGFR expression of carcinoma cells.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsErbB ReceptorsEstradiolEstrogensFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMCF-7 CellsMicroRNAsMiddle AgedEGFR protein, humanErbB ReceptorsEstradiolEstrogensMicroRNAsMIRN7-1 microRNA, human

Identifiers

PMID23227519
PMCPMC3445861
OpenAlexW2159054485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.